recombinant BMS-191352 protein

a single-chain fusion protein composed of the variable regions of chimeric BR96 monoclonal antibody and the binding defective form of Pseudomonas Exotoxin A, PE40

Also Known As:

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bookman, Michael A: 1 article (10/2002)
2.	Carey, Delicia E: 1 article (10/2002)
3.	Grizzle, William E: 1 article (10/2002)
4.	Khazaeli, Mohammad B: 1 article (10/2002)
5.	LoBuglio, Albert F: 1 article (10/2002)
6.	Lorenz, Jennifer M: 1 article (10/2002)
7.	Nowrouzi, Anahit: 1 article (10/2002)
8.	Posey, James A: 1 article (10/2002)
9.	Saleh, Mansoor N: 1 article (10/2002)
10.	Siegall, Clay B: 1 article (10/2002)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2002 - "A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors." 09/01/2001 - "Seattle Genetics is developing SGN-10 (BR96-SCIT), a single-chain immunotoxin (SCIT) under license from Bristol-Myers Squibb (BMS), as both a monotherapy and in combination with Taxotere (Rhône-Poulenc Rorer) for the potential treatment for cancer [308773]. "
2.	Carcinoma (Carcinomatosis) 10/01/2002 - "A total of 46 patients with Le(Y)-positive metastatic carcinoma were enrolled in a Phase I dose-escalation study in cohorts of three to six patients who received SGN-10 at doses ranging from 0.024 to 0.962 mg/m(2), administered on days 1, 4, 8, and 11, followed by 2 weeks of rest and a second cycle of therapy. "

Related Drugs and Biologics

1.	Immunotoxins (Immunotoxin)
2.	Docetaxel (Taxotere)

Related Therapies and Procedures

1.	Therapeutics